May 30, 2024

Patholytix 4.0, Becomes First Platform to Support Future-proof Study Archival of Regulated Digital Safety Studies

DUBLIN, Ireland, May 30, 2024—Deciphex, a pioneering leader in GLP-compliant digital pathology solutions, announces today that it is the first DICOM-native platform to fully facilitate the archival and reconstruction of regulated digital studies. Previously unavailable, this advancement strengthens digital pathology's use in GLP drug safety assessment.

DICOM (Digital Imaging and Communications in Medicine) is a foundational standard for transmitting, storing, and managing medical imaging information globally, ensuring seamless interoperability between systems across different facilities. A lack of consistency in image formats, metadata, and interoperability has previously posed challenges across the non-clinical industry. Consistent and standardised digital slide storage via native DICOMWSI streamlines archival, retrieval, and management of pathology data as seen with DICOM's successful adoption within Radiology.

By being the first non-clinical workflow to implement end to end DICOM natively, Patholytix 4.0 enhances the accessibility and usability of GLP studies’ data. This provides a vital solution addressing long-term archival and accessibility of digital study data. 

Pierre Moulin, Chief Scientific Officer at Deciphex emphasised the significance of this milestone:

"Implementing DICOM in our platform underscores Deciphex’s commitment to open standards and long-term client needs. This approach ensures that even if our platform evolves, the data remains accessible and usable for retrospective studies and innovative analyses."

He added,

"The implementation of DICOM in Patholytix 4.0 not only future-proofs the archival of GLP studies but also ensures unparalleled consistency and interoperability in digital pathology. This advancement allows seamless data sharing and integration across various platforms and facilities, ultimately driving innovation and efficiency in the field."

This advancement aims to enhance the reliability and accessibility of critical data and represents a significant step forward in enabling robust and reproducible digital pathology workflows.

For more information about Deciphex and Patholytix 4.0, please visit Patholytix.com

About Deciphex:

Deciphex is a pioneering company at the forefront of the digital transformation of pathology. By networking with global pathologists and leveraging AI-driven solutions, Deciphex accelerates certainty in pathology reporting, ultimately enhancing patient care and advancing drug development. For more information, visit https://www.deciphex.com.

For media inquiries, please contact:

Charli-Ann Lynch
Product Marketing Specialist
[email protected]
+353 872401459

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
return to news

Contact Details

Invent Buidling at DCU

Ireland

Deciphex
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
D11 KXN4

Call: +353 1 582 7193

Email: [email protected]

Twitter: @deciphex

USA

Deciphex Inc.
500 E Diehl RoadSuite 130,
Naperville,
IL 60563

Call: +1 708 573 0674

Email: [email protected]

USA Headquarters Building

UK

Diagnexia
Hedy Lamarr Building,
3 Babbage Way,
Exeter,
EX5 2FN

Call: +44 1 29730 2245

Email: [email protected]

UK

Oxford Accessioning Centre (UK)
Diagnexia UK Ltd,
Building B,
‍Langford Locks,
Kidlington,
OX5 1LH

Email Us

The details you submit will be used so that we can contact you in relation to your query either by email or your preferred method of contact. Read our privacy policy here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form
Copyright Deciphex 2021
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.